... translation. The overall findings demonstrate the utility of phosphoproteomics to identify EC-protective agents to mitigate cardio-oncology side effects. Correspondence: Iris Z. Jaffe ( [email protected] ) 26 03 2024 27 07 2024 28 08 2024 29 08 2024 © 2024...

... cardiovascular sequelae. Therefore, a comprehensive baseline assessment and adequate monitoring by specialised cardio-oncology teams is essential in case these agents are used in combination, particularly in high-risk patients. This review summarises the mechanisms of action and treatment indications...

... cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic...

... in extrahepatic tissues [ 8 ]. Of importance in cardio-oncology, CYP1B1 has been shown to be expressed in cardiovascular tissues and overexpressed in malignant tumors. Indeed, CYP1B1 has been detected at the mRNA and protein levels in cardiovascular tissues of human and experimental animals [ 15 ]. CYP1B1 mRNA...

... arrhythmia cardio-oncology cardiotoxicity chemotherapy heart failure PI3Kα The phosphoinositide 3-kinases (PI3Ks) are a family of intracellular lipid kinases that phosphorylate the 3′-hydroxyl group of inositol membrane lipids [ 1 , 2 ]. These enzymes integrate extracellular stimuli to modulate...

... [email protected] ). 1 6 2016 17 10 2016 3 11 2016 © 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society 2016 cardio-oncology chemotherapy heart failure Heart disease and cancer are the top two causes of mortality globally...